海马谷氨酸水平与精神病临床高危个体不良结局的关联
该横断面研究纳入86例精神病临床高危个体和30名健康对照,平均随访18.5个月,发现基线左侧海马谷氨酸水平较高与后续转化为精神病及功能结局不良相关,肌醇和肌酸水平也呈现类似关联。
要点
- 海马肌醇和肌酸水平在转化为精神病的高危个体中升高。
核心结论
- 精神病临床高危个体的不良临床结局可能与基线海马谷氨酸水平升高以及肌醇和肌酸水平升高相关。
- 这些指标可能有助于按未来临床结局对临床高危个体进行分层。
研究设计与样本
- 横断面研究,纳入86例精神病临床高危个体和30名健康对照,平均随访18.5个月,于2011年11月1日至2017年11月1日在英国伦敦和剑桥的早期检测服务机构开展。
- 采用3-T质子磁共振波谱在首次临床就诊时测量左侧海马谷氨酸及其他代谢物浓度。
- 随访时使用CAARMS标准评估是否转化为精神病,使用GAF量表评估整体功能水平。
主要发现
- 随访时12例临床高危个体发展为精神病首发,74例未转化;19例临床高危个体功能结局良好(GAF≥65),38例功能结局不良(GAF<65)。
临床怎么用
- 对精神病临床高危个体,可考虑检测基线海马谷氨酸、肌醇和肌酸水平以辅助评估未来转化为精神病及功能结局不良的风险。
- 上述代谢物指标可能有助于对临床高危个体进行分层管理,但需进一步验证。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preclinical and human data suggest that hippocampal dysfunction plays a critical role in the onset of psychosis. Neural hyperactivity in the hippocampus is thought to drive an increase in subcortical dopamine function through glutamatergic projections to the striatum. OBJECTIVE: To examine the association between hippocampal glutamate levels in individuals at clinical high risk for psychosis and their subsequent clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study of 86 individuals at clinical high risk for psychosis and 30 healthy control individuals, with a mean follow-up of 18.5 months, was conducted between November 1, 2011, and November 1, 2017, at early detection services in London and Cambridge, United Kingdom. MAIN OUTCOMES AND MEASURES: Concentrations of glutamate and other metabolites were measured in the left hippocampus using 3-T proton magnetic resonance spectroscopy at the first clinical presentation. At follow-up, clinical outcomes were assessed in terms of transition or nontransition to psychosis using the Comprehensive Assessment of the At-Risk Mental State criteria and the level of overall functioning using the Global Assessment of Function scale. RESULTS: Of 116 total participants, 86 were at clinical high risk for psychosis (50 [58%] male; mean [SD] age, 22.4 [3.5] years) and 30 were healthy controls (14 [47%] male; mean [SD] age, 24.7 [3.8] years). At follow-up, 12 clinical high-risk individuals developed a first episode of psychosis whereas 74 clinical high-risk individuals did not; 19 clinical high-risk individuals showed good overall functioning (Global Assessment of Function ≥65), whereas 38 clinical high-risk individuals had a poor functional outcome (Global Assessment of Function <65). Compared with clinical high-risk individuals who did not become psychotic, clinical high-risk individuals who developed psychosis showed higher hippocampal glutamate levels (mean [SD], 8.33 [1.48] vs 9.16 [1.28] glutamate levels; P = .048). The clinical high-risk individuals who developed psychosis also had higher myo-inositol levels (mean [SD], 7.60 [1.23] vs 6.24 [1.36] myo-inositol levels; P = .002) and higher creatine levels (mean [SD], 8.18 [0.74] vs 7.32 [1.09] creatine levels; P = .01) compared with clinical high-risk individuals who did not become psychotic, and higher myo-inositol levels compared with healthy controls (mean [SD], 7.60 [1.23] vs 6.19 [1.51] myo-inositol levels; P = .005). Higher hippocampal glutamate levels in clinical high-risk individuals were also associated with a poor functional outcome (mean [SD], 8.83 [1.43] vs 7.76 [1.40] glutamate levels; P = .02). In the logistic regression analyses, hippocampal glutamate levels were significantly associated with clinical outcome in terms of transition and nontransition to psychosis (β = 0.48; odds ratio = 1.61; 95% CI, 1.00-2.59; P = .05) and overall functioning (β = 0.53; odds ratio = 1.71; 95% CI, 1.10-2.66; P = .02). CONCLUSIONS AND RELEVANCE: The findings indicate that adverse clinical outcomes in individuals at clinical high risk for psychosis may be associated with an increase in baseline hippocampal glutamate levels, as well as an increase in myo-inositol and creatine levels. This conclusion suggests that these measures could contribute to the stratification of clinical high-risk individuals according to future clinical outcomes.
引用
- Bossong MG, Antoniades M, Azis M, et al. Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry. 2019. PMID: 30427993. doi:10.1001/jamapsychiatry.2018.3252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。